NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Long-term Debt
Borrowings due after more than one year.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $0, compared with $0 a year earlier.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 5.01M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 2.82M | — |
| FY2021 | 2021-12-31 | 0 | — |
Long-term Debt vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 long-term debt of $0 is the 6th highest of the 9 companies compared; the peer median is $2.86M.
- Long-term debt amounts to 0.0% of total assets for NRXP, versus a peer median of 5.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $192.16M | +24.1% | +6.6% | 146.2% | |
| Mar 2026 | $43.94M | — | — | 13.5% | |
| Mar 2026 | $11.12M | -47.1% | — | 50.8% | |
| Mar 2026 | $5.46M | — | -49.7% | 9.7% | |
| Mar 2026 | $251K | — | -52.1% | 0.4% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | +0.0% | 0.0% | |
| Peer median (excluding NRXP) | $2.86M | -73.6% | -24.9% | 5.1% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.